Prognostic Score Including Gene Mutations in Chronic Myelomonocytic LeukemiaRaphaël Itzykson, Éric Solary, Torsten Haferlach et al.|Journal of Clinical Oncology|2013Cited by 543
Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemiasRaphaël Itzykson, Olivier Kosmider, Thomas Cluzeau et al.|Leukemia|2011Cited by 464
Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 studyCéline Berthon, Hervé Dombret, Emmanuel Raffoux et al.|The Lancet Haematology|2016Cited by 431
Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemiaÉric Jourdan, Hervé Dombret, Nicolas Boissel et al.|Blood|2013Cited by 357
Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With<i>NPM1</i>Mutation: A Study by the Acute Leukemia French Association GroupMarie Balsat, Nicolas Boissel, Aline Renneville et al.|Journal of Clinical Oncology|2017Cited by 292